Posted by Michael Wonder on 16 Aug 2022
Otsuka Canada Pharmaceutical announces Health Canada approval of Korsuva (difelikefalin) for the treatment of moderate to severe pruritus associated with chronic kidney disease in adult haemodialysis patients
16 August 2022 - Launch of Korsuva in Canada is expected in the second quarter of 2023.
Otsuka Canada Pharmaceutical today announced that Health Canada has approved Korsuva (difelikefalin) injection for the treatment of moderate to severe pruritus associated with chronic kidney disease in adults undergoing haemodialysis.
